Analyst Price Targets — AUTL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 18, 2024 11:08 am | Graig Suvannavejh | Goldman Sachs | $7.60 | $3.03 | StreetInsider | Goldman Sachs Upgrades Autolus Therapeutics plc (AUTL) to Buy |
| May 20, 2024 6:43 am | Yanan Zhu | Wells Fargo | $8.00 | $4.39 | StreetInsider | Wells Fargo Reiterates Overweight Rating on Autolus Therapeutics plc (AUTL) |
| April 8, 2024 12:28 pm | Asthika Goonewardene | Truist Financial | $11.00 | $5.53 | StreetInsider | Autolus Therapeutics plc (AUTL) PT Raised to $11 at Truist Securities |
| March 15, 2024 8:28 am | Asthika Goonewardene | Truist Financial | $10.00 | $5.82 | StreetInsider | Autolus Therapeutics plc (AUTL) PT Raised to $10 at Truist Securities |
Latest News for AUTL
Oncology innovation is reshaping cancer care as AI, immunotherapy and targeted therapies fuel pipeline growth and spotlight promising cancer-focused stocks.
LONDON & GAITHERSBURG, Md., July 01, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Compensation Committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 25,420 American Depositary…
LONDON and GAITHERSBURG, Md., June 25, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announced that the Company will participate in the H.C.
LONDON and GAITHERSBURG, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Galien Foundation has presented the Company with the 2026 Prix Galien UK Award for Best Biotechnology Product.
After losing some value lately, a hammer chart pattern has been formed for Autolus Therapeutics (AUTL), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AUTL.
U.S. House Trading
No House trades found for AUTL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.